Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Grows By 122.8%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 579,800 shares, a growth of 122.8% from the September 15th total of 260,200 shares. Based on an average daily volume of 305,800 shares, the short-interest ratio is presently 1.9 days. Approximately 12.6% of the company’s shares are short sold. Approximately 12.6% of the company’s shares are short sold. Based on an average daily volume of 305,800 shares, the short-interest ratio is presently 1.9 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. EWA LLC purchased a new position in shares of Vivos Therapeutics in the first quarter valued at $30,000. XTX Topco Ltd purchased a new position in shares of Vivos Therapeutics in the second quarter valued at $65,000. Cutter & CO Brokerage Inc. boosted its stake in shares of Vivos Therapeutics by 28.9% in the first quarter. Cutter & CO Brokerage Inc. now owns 49,100 shares of the company’s stock valued at $140,000 after purchasing an additional 11,000 shares during the period. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Vivos Therapeutics in the second quarter valued at $220,000. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Vivos Therapeutics Price Performance

Vivos Therapeutics stock opened at $2.90 on Monday. Vivos Therapeutics has a 52-week low of $1.98 and a 52-week high of $7.95. The firm has a fifty day moving average of $3.76 and a 200-day moving average of $3.49. The firm has a market capitalization of $21.75 million, a P/E ratio of -1.73 and a beta of 6.90. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 1.69.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings data on Tuesday, August 19th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.16). The business had revenue of $3.82 million during the quarter, compared to analyst estimates of $3.37 million. Vivos Therapeutics had a negative return on equity of 232.76% and a negative net margin of 99.49%. As a group, analysts predict that Vivos Therapeutics will post -1.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on VVOS shares. Ascendiant Capital Markets upped their price target on shares of Vivos Therapeutics from $6.20 to $6.50 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 10th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.92.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.